Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck Settles Class Suit Targeting Coppertone Claims, Denies Wrongdoing

This article was originally published in The Tan Sheet

Executive Summary

Merck agrees to pay a maximum of $10 million to consumers to settle class-action case and to comply with labeling and claims regulations that will become law in December for most firms under an FDA final rule. The settlement in federal court resolves separate litigation against Coppertone filed in California state court.

You may also be interested in...



Merck Faces Consumer Suit Over Coppertone UV Claims

A lawsuit filed in federal court in New Jersey alleges Merck has misrepresented the UV-protective benefits of its Coppertone sunscreen products, subjecting consumers to potential risks.

FDA Questions Spray Sunscreen Safety, Efficacy And Monograph Status

FDA could exclude increasingly popular spray sunscreens from the final monograph unless firms submit sufficient safety and efficacy data, according to an advanced notice of proposed rulemaking.

Schering-Plough Merger Offers Merck OTC Business, Zegerid Switch Rights

Merck stands to pick up the switch rights to the proton pump inhibitor Zegerid at the head of a strong switch program if its planned acquisition of Schering-Plough succeeds

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS106003

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel